Croda's interims strike a confident tone confirming a continued improvement in underlying sales, strong margins and 7% PBT growth. This was underpinned by record sales of New and Protected products. Life Sciences is again the stand out performer, reporting 15% revenue growth on the back of the Omega 3 product launch. Encouragingly, Q2 sales were ahead of Q1. Full year expectations are reiterated, despite tougher comps from H2. We expect to retain our forecasts. Croda is a Group of the highest qu ....
21 Jul 2015
Confident interims confirm on track for a return to growth
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Confident interims confirm on track for a return to growth
Croda International Plc (CRDA:LON) | 4,884 1318.8 0.6% | Mkt Cap: 6,820m
- Published:
21 Jul 2015 -
Author:
James Tetley -
Pages:
3
Croda's interims strike a confident tone confirming a continued improvement in underlying sales, strong margins and 7% PBT growth. This was underpinned by record sales of New and Protected products. Life Sciences is again the stand out performer, reporting 15% revenue growth on the back of the Omega 3 product launch. Encouragingly, Q2 sales were ahead of Q1. Full year expectations are reiterated, despite tougher comps from H2. We expect to retain our forecasts. Croda is a Group of the highest qu ....